ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › Immunohistochemistry
Sample & Methods — Step 2 of 3
1FFPE
2IHC
3TMA
Previous
FFPE Next
TMA
Current Standard

Immunohistochemistry

The expression-based detection standard since 1941–a one-site assay limited by subjectivity and inability to report function.

View
Definition
Immunohistochemistry uses antibodies to detect protein expression in tissue sections, visualized through enzymatic or fluorescent reporters. As a one-site assay, IHC reports only that a protein is present–not whether it is functionally engaged. This fundamental limitation drives the need for functional biomarkersLoading... that measure interaction state.
Video Segments
JCO Clinical Study: 188 NSCLC Patients
Primary
Antibody QC & Clone Selection
Primary
Related Segments
The QF-Pro Reagent Kit & Workflow
Related
One-site detection
Reports presence only
Subjective scoring
Operator-dependent
Expression ≠ function
Fundamental limitation
80+ years clinical use
Established infrastructure

Strengths of the Current Standard

Immunohistochemistry has been the workhorse of diagnostic pathology since Albert Coons developed immunofluorescence in 1941. Its strengths are substantial and explain its enduring clinical role.

Universal availability: Every pathology laboratory worldwide performs IHC. Equipment, reagents, and expertise are ubiquitous. This infrastructure represents billions of dollars of investment and decades of training.

Regulatory precedent: Dozens of FDA-approved companion diagnosticsLoading... use IHC as the detection method. The regulatory pathway is well-established, with clear guidance on analytical and clinical validation requirements.

Morphological context: IHC preserves tissue architecture, enabling pathologists to assess protein expression within specific cell types and anatomical compartments. This spatial information guides clinical interpretation.

Simplified

Why IHC Is Used: Immunohistochemistry is established, relatively inexpensive, widely available, and provides spatial information about where proteins are located in tissue.

Proven Value: IHC-based tests guide treatment selection for many cancers (HER2, ER, PR, PD-L1).

The Fundamental Limitation

Despite its clinical success, IHC has a fundamental architectural limitation: it is a one-site assay. A single antibody binds to a single epitope, reporting only that the target protein is present above detection threshold.

This architecture cannot distinguish between:

* A receptor bound to its ligand (functionally engaged)
* A receptor unbound and inactive (merely expressed)
* A protein in its active conformation versus inactive state

The clinical consequence is profound. PD-L1 IHC–the companion diagnostic for checkpoint inhibitorLoading... therapy–measures how much PD-L1 is expressed but cannot determine whether PD-1/PD-L1Loading... engagement is actually occurring. This explains why PD-L1 expression fails to predict immunotherapy response (p=0.87 in melanoma), while PD-1/PD-L1 interaction state measured by iFRETLoading... shows significant correlation (p=0.05).

The solution is not to abandon IHC but to supplement it with two-site assays that can report on protein interactions and functional states.

Simplified

What IHC Can't Tell You: IHC measures presence and approximate abundance—not function. It can't distinguish active from inactive proteins, or tell if two proteins are interacting.

The Gap: This is why PD-L1 IHC imperfectly predicts checkpoint inhibitor response. Presence doesn't equal engagement doesn't equal function.

One-Site Detection (IHC)
"Is the protein expressed?"
Presence above threshold
Subjective scoring (0, 1+, 2+, 3+)
Expression != therapeutic response
Two-Site Detection (FRET)
"Is the protein functionally engaged?"
Interaction at 1–10 nm
Quantitative FRET efficiency (%)
Engagement predicts response

Clinical Evidence: IHC Limitations

  • PD-L1 in melanomaLoading...: Expression by IHC showed no correlation with overall survival (p=0.87), while interaction state by iFRETLoading... was significantly predictive (p=0.05)
  • PD-L1 negative patients: 10 of 11 patients classified as 'PD-L1 negative' by IHC showed PD-1/PD-L1Loading... interaction by iFRET–functional engagement invisible to expression-based detection
  • Akt in breast cancer: IHC intensity ratio showed no prognostic value; FRETLoading...-measured activation predicted disease-free and overall survival
  • Scoring variability: Inter-observer agreement for PD-L1 IHC scoring ranges from 52–87% depending on antibody clone and training–introducing uncertainty at clinical decision points

Connected Terms

Share This Term
Term Connections